Real-world Trial of Individualized Precision Oncology

The goal of this clinical trial is to learn if drugs that are matched to tumor DNA mutations work to treat metastatic solid cancers in adults. The main questions it aims to answer are: Is tumor worsening delayed for a longer period of time if patients take drugs that match DNA mutations, compared to if they take standard of care drugs? Researchers will compare drugs matched to tumor DNA mutations to standard of care drugs to see if the matched drugs work better, and to see if tumor worsening can be delayed for longer the more DNA mutations the drugs target. Participants will: Take drugs matched to tumor DNA mutations or standard of care drugs based on the regular dosing schedule of the drugs. Visit the clinic every approximately 2 months for checkups and tumor imaging.

NCT Number	NCT07346209
Lead Sponsor	University of California, San Diego
Conditions	Metastatic Cancer, Unresectable Carcinoma
Enrollment	280 participants
Start Date	2026-06
Primary Completion	2031-03 (estimated)
Study Completion	2031-09 (estimated)
Updated on ClinicalTrials.gov	2026-04-08